XML 28 R10.htm IDEA: XBRL DOCUMENT
v3.22.4

Revenue Recognition | 12 Months Ended
--- | ---
Dec. 31, 2022
Text Block [Abstract] |
Revenue from Contract with Customer | Revenue recognition and accounts receivable The Company's revenues by segment and primary payor source were as follows:
| Year ended December 31, 2022
| U.S. dialysis |  | Other - Ancillary services |  | Consolidated
Patient service revenues: |  |  |  |  |
Medicare and Medicare Advantage | $ | 6,041,496 |  |  |  |  | $ | 6,041,496 |
Medicaid and Managed Medicaid | 759,579 |  |  |  |  | 759,579 |
Other government | 336,991 |  |  | 464,921 |  |  | 801,912 |
Commercial | 3,437,306 |  |  | 223,216 |  |  | 3,660,522 |
Other revenues: |  |  |  |  |
Medicare and Medicare Advantage |  |  | 345,340 |  |  | 345,340 |
Medicaid and Managed Medicaid |  |  | 1,546 |  |  | 1,546 |
Commercial |  |  | 22,211 |  |  | 22,211 |
Other(1) | 24,437 |  |  | 44,092 |  |  | 68,529 |
Eliminations of intersegment revenues | (87,035) |  |  | (4,206) |  |  | (91,241) |
Total | $ | 10,512,774 |  |  | $ | 1,097,120 |  |  | $ | 11,609,894 |
(1)Other consists primarily of management service fees earned in the respective Company line of business as well as other non-patient service revenue from the Company's U.S. IKC and other ancillary services and international operations.
| Year ended December 31, 2021
| U.S. dialysis |  | Other - Ancillary services |  | Consolidated
Patient service revenues: |  |  |  |  |
Medicare and Medicare Advantage | $ | 6,133,235 |  |  | $ |  | $ | 6,133,235 |
Medicaid and Managed Medicaid | 782,430 |  |  |  |  | 782,430 |
Other government | 328,256 |  |  | 463,385 |  |  | 791,641 |
Commercial | 3,397,697 |  |  | 199,024 |  |  | 3,596,721 |
Other revenues: |  |  |  |  |
Medicare and Medicare Advantage |  |  | 326,696 |  |  | 326,696 |
Medicaid and Managed Medicaid |  |  | 1,321 |  |  | 1,321 |
Commercial |  |  | 15,553 |  |  | 15,553 |
Other(1) | 25,345 |  |  | 40,945 |  |  | 66,290 |
Eliminations of intersegment revenues | (90,796) |  |  | (4,294) |  |  | (95,090) |
Total | $ | 10,576,167 |  |  | $ | 1,042,630 |  |  | $ | 11,618,797 |
(1)Other consists primarily of management service fees earned in the respective Company line of business as well as other non-patient service revenue from the Company's U.S. IKC and other ancillary services and international operations.
| Year ended December 31, 2020
| U.S. dialysis |  | Other - Ancillary services |  | Consolidated
Patient service revenues: |  |  |  |  |
Medicare and Medicare Advantage(1) | $ | 6,169,226 |  |  | $ |  | $ | 6,169,226 |
Medicaid and Managed Medicaid | 744,862 |  |  |  |  | 744,862 |
Other government(1) | 334,714 |  |  | 380,584 |  |  | 715,298 |
Commercial | 3,370,562 |  |  | 170,394 |  |  | 3,540,956 |
Other revenues: |  |  |  |  |
Medicare and Medicare Advantage |  |  | 419,662 |  |  | 419,662 |
Medicaid and Managed Medicaid |  |  | 1,227 |  |  | 1,227 |
Commercial |  |  | 33,246 |  |  | 33,246 |
Other(2) | 40,571 |  |  | 47,585 |  |  | 88,156 |
Eliminations of intersegment revenues | (145,286) |  |  | (16,743) |  |  | (162,029) |
Total | $ | 10,514,649 |  |  | $ | 1,035,955 |  |  | $ | 11,550,604 |
(1)During the first quarter of 2021, the Company realigned the classification of revenue previously disclosed in the "Other government" category to the "Medicare and Medicare Advantage" category for certain government-reimbursed plans which have structure and payment characteristics similar to traditional Medicare Advantage plans. The classification of revenue for these plans for the year ended December 31, 2020 has also been recast to conform to this presentation. (2)Other consists primarily of management service fees earned in the respective Company line of business as well as other non-patient revenue from the Company's U.S. IKC and other ancillary services and international operations. The majority of the Company's non-patient service revenues from Medicare and Medicare Advantage, Medicaid and Managed Medicaid, and commercial sources represent risk-based revenues earned by the Company's U.S. integrated care and disease management business. As described in Note 1, there are significant risks associated with estimating revenue, many of which take several years to resolve. These estimates are subject to ongoing insurance coverage changes, geographic coverage differences, differing interpretations of contract coverage and other payor issues, as well as patient issues including determining applicable primary and secondary coverage, changes in patient coverage and coordination of benefits. As these estimates are refined over time, both positive and negative adjustments to revenue are recognized in the current period. No single commercial payor accounted for more than 10% of consolidated revenues or consolidated accounts receivable for the periods presented in these consolidated financial statements or at their period-ends, respectively. Dialysis services accounts receivable and other receivables from Medicare, including Medicare Advantage plans, and Medicaid, including managed Medicaid plans, were approximately $1,113,499 and $1,174,123 as of December 31, 2022 and 2021, respectively. Approximately 18% and 16% of the Company’s patient services accounts receivable balances as of December 31, 2022 and 2021, respectively, were more than six months old. There were no significant balances over one year old at December 31, 2022. The Company's accounts receivable are principally due from Medicare and Medicaid programs and commercial insurance plans.

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI https://asc.fasb.org/topic&trid=49130388 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(2) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration